TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Stopped The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.

Conditions

• Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
• Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

Interventions

• DRUG: TAS-117
• DRUG: TAS-117
• DRUG: TAS-117
• DRUG: TAS-117

Sponsor

Taiho Oncology, Inc.